biophysical properties. We will continue exploring its therapeutic potential to benefit patients worldwide." On January 10, 2025, Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech") entered into a global licensing...
industry. Most recently, he served as CFO at Proteome Sciences plc and Paion AG where he successfully secured more than €150mln in financing and played a pivotal role in establishing key commercial infrastructure across Europe. Earlier in this...
for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United...
is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on...
and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For...
the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only...
fully enrolled, Phase 2, randomized, controlled study evaluating the safety, efficacy and tolerability of laru-zova in 14 male patients with XLRP caused by mutations in the RPGR gene. The study's primary endpoint is the proportion of response by...
cutaneous dose-limiting toxicity, announced that it has secured a $30 million financing to advance the development of LUT014, an innovative topically applied gel aimed at reducing EGFRi-induced rashes, a common adverse side effect of these...
progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic's lead asset STM-01. Under this partnership, Cellipont Bioservices will provide technology transfer, analytical method transfer, and cGMP...
This one-step press-fit solution for vial closure is offered in ready-to-use, validated formats compatible with vials with 13mm and 20 mm crowns. The new 6x8 nested tub configuration supports the West 10ml nested CZ vials as well as selected nested...
achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary oral agent AX-158. These results confirm the strong Phase 1 and preclinical data package, underscoring the potential breadth and depth of Nck...
million cases in 2023, according to the World Health Organization. Despite the expenditure of $4 billion per year on control1, malaria deaths and cases have not substantively changed over the last decade. Consequently, a safe, effective,...
Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T candidate to...
with limited options and a bleak prognosis. This open-label, dose-escalation trial, conducted at two sites, involved 12 participants with genetically confirmed BCD. Participants received a single subretinal injection of either 1.5 e11 or 3.0e11...
a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 100 published patent families.
RNA in continuous flow and can scale seamlessly from small research doses to commercial volumes. NTxscribe produces 10-50 mg of high integrity RNA in two hours, shortening timelines for bringing new therapies and vaccines to market and empowering...
Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three...
immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG...
advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study was...
Dr. Howard Murad, a 1962 graduate of Long Island University's Arnold & Marie Schwartz College of Pharmacy and Health Sciences and an internationally recognized innovator in the science of skin care, is establishing the Dr. Howard Murad '62...